Li Kai, Qu Shuai, Chen Xi, Wu Qiong, Shi Ming
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China.
Int J Mol Sci. 2017 Feb 14;18(2):404. doi: 10.3390/ijms18020404.
Malignant cancers employ diverse and intricate immune evasion strategies, which lead to inadequately effective responses of many clinical cancer therapies. However, emerging data suggest that activation of the tolerant innate immune system in cancer patients is able, at least partially, to counteract tumor-induced immunosuppression, which indicates triggering of the innate immune response as a novel immunotherapeutic strategy may result in improved therapeutic outcomes for cancer patients. The promising innate immune targets include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Stimulator of Interferon Genes (STING). This review discusses the antitumor properties of TLRs, RLRs, and STING-mediated innate immune pathways, as well as the promising innate immune targets for potential application in cancer immunotherapy.
恶性肿瘤采用多样且复杂的免疫逃逸策略，这导致许多临床癌症治疗的反应效果不佳。然而，新出现的数据表明，激活癌症患者体内的耐受性先天免疫系统至少能部分抵消肿瘤诱导的免疫抑制，这表明触发先天免疫反应作为一种新的免疫治疗策略可能会改善癌症患者的治疗效果。有前景的先天免疫靶点包括Toll样受体（TLRs）、维甲酸诱导基因I样受体（RLRs）和干扰素基因刺激因子（STING）。本文综述了TLRs、RLRs和STING介导的先天免疫途径的抗肿瘤特性，以及在癌症免疫治疗中具有潜在应用前景的先天免疫靶点。
